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ABSTRACT  
 
While mammary Paget’s disease (MPD) is clearly linked to breast cancer, 
histogenesis of extramammary Paget’s disease (EMPD) is controversial. Recently NY-
BR-1, a differentiation antigen expressed in the breast and in skin adnexal structures 
was identified. Its protein expression is restricted to normal and neoplastic breast 
epithelium and to adnexal tumors of the skin.  
In this study, we examined NY-BR-1 expression by immunohistochemistry in 24 
MPD cases with synchronous ductal carcinoma in situ or invasive breast cancer. 
Results were compared with 26 cases of EMPDs of men (n=4) and women (n=22) as 
well as in apo-eccrine glands of the axilla and mammary-like glands of the ano-
genital region. We found NY-BR-1 positivity in 18 of 24 MPDs (75%) and in 21 of 
26 EMPDs (80.8%). All apo-eccrine glands of the axilla and mammary-like glands of 
the ano-genital region were NY-BR-1 positive.  
NY-BR-1 expression is a common finding in MPD and in EMPD. When considering 
the diagnosis of Paget’s disease, NY-BR-1 is a useful diagnostic marker. Furthermore 
NY-BR-1 positivity in apo-eccrine glands of the axilla and ano-genital region 
suggests a potential histogenetic link between these structures and Paget’s disease.  
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INTRODUCTION 
Paget’s disease is subdivided into mammary Paget’s disease (MPD) and 
extramammary Paget’s disease (EMPD). Over 95% of MPDs are associated with an 
underlying in-situ or invasive ductal carcinoma of the breast, whereas the remaining 
five percent are believed to arise from Toker cells of the skin or from pluripotent stem 
cells 1-5.  
EMPD was first described by Crocker in 1889 in a patient with urinary bladder 
carcinoma who presented an eczematous lesion of the scrotum and penis 6. EMPD is 
mainly observed in skin regions that are rich in apocrine and apo-eccrine glands 7 and 
thus most commonly affects the external female ano-genital region 8 as well as the 
axilla, umbilicus, eyelids and external ear channel 9-11. Cells in the so-called 
mammary-like glands (MLGs) 12-13 of the ano-genital region, or in the skin adherence 
glands, Toker cells of the epidermis, pluripotent stem cells 4, 14-15 and infiltrating 
urothelial carcinomas with involvement of the epidermis 8 have been discussed as 
histogenetic origins of EMPD. 
NY-BR-1 is a recently isolated differentiation antigen 16. The NY-BR-1 protein is 
expressed in normal and in neoplastic breast epithelium, skin andexal tumors 17-18 and 
in MLGs of the ano-genital region 19. The NY-BR-1 gene was identified by SEREX 
analysis (Serological Analysis of Recombinant Expression libraries) of a patient with 
metastatic breast carcinoma. The NY-BR-1 gene is located on chromosome 10p11-p12 
and is composed of 37 exons. It encodes a peptide of MW 150,000-160,000, a 
putative transcription factor 20. As an official Hugo name, NY-BR-1 has been 
designated as ANKRD30A. Although NY-BR-1 mRNA could be detected in different 
organs such as testis or the prostate, its protein expression is restricted to normal and 
neoplastic breast epithelium and adnexal tumors of the skin 18, 21. NY-BR-1 is 
therefore classified as a differentiation antigen of the mammary gland. Our recent 
immunohistochemical studies have shown that NY-BR-1 is expressed in about 60% 
of breast cancers 17-18, 21. Due to its organ-specificity, NY-BR-1 can potentially be 
used for diagnostic purposes in surgical pathology. NY-BR-1 protein expression has 
not been studied yet in Paget’s disease. 
Here, we performed an immunohistochemical NY-BR-1 expression analysis in a 
series of MPDs and EMPDs to determine the prevalence of this breast differentiation 
antigen in such lesions. Further, NY-BR-1 expression was analyzed in a larger series 
of apo-eccrine glands of the axilla and MLGs of the anogenital region. Frequent NY-
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BR-1 positivity in MPD and EMPD prompted us to speculate that NY-BR-1 
immunoreactivity can be used as a tool for differential diagnosis in biopsy specimens. 
Since the differential diagnosis of Paget’s disease includes Toker cells of the skin,  
M. Bowen or pagetoid melanoma, we compared NY-BR-1 expression in EMPD with 
an antibody panel including CK7, CK20, CEA and GCDFP-15.  
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MATERIALS AND METHODS  
 
Mammary Paget’s disease 
Twenty-four female patients with MPD were selected from the archives of the 
Institute of Surgical Pathology of the University Hospital of Zurich, Switzerland. The 
age ranged from 40 to 80 years (median 61 years) at diagnosis. In surgical specimens 
after MPD diagnosis, 21 breast resection specimens (87.5%) showed an underlying 
ductal carcinoma in situ (DCIS) or invasive ductal cancer. 
 
Extramammary Paget’s disease 
Tissue from 26 consecutive patients diagnosed with EMPD from 1982 to 2007 was 
retrieved from the archives of the Surgical Pathology Institute of the University 
Hospital of Zurich, Zurich, Switzerland and the Cantonal Hospital of St. Gallen, St. 
Gallen, Switzerland. The patients’ ages ranged from 44 to 89 years (median 73 years). 
There were 22 female and 4 male patients. Twenty-one EMPDs were located in the 
vulva, one was paravulvar, one orginated from the perianal region (male patient), two 
from the anal region (both male patients) and one from the preputium. 
In six patients, tissue from recurrent EMPD was available in follow-up biopsies 
(between 2 and 24 years after first diagnosis). In all patients with EMPD no regional 
invasive carcinoma was known at the time of primary EMPD manifestation or during 
follow-up. 
 
Control cases 
A tissue micro-array with 382 endometrial cancers was analyzed for the presence of 
NY-BR-1 expression as an additional marker in the differential diagnosis of EMPD. 
12 cases of in situ squamous carcinoma of the skin (Bowen’s disease) were also 
selected and examined on whole tissue sections. Selection criteria for Bowen disease 
included diagnostic morphological features for in situ carcinoma of the skin without 
evidence of glandular cells within the epidermis. 
48 skin samples from the axillary regions of 24 patients with mammary Paget’s 
disease were also evaluated for the presence of apo-eccrine glands. Eccrine glands 
were present in all samples, apocrine glands in 19 and sebaceous glands in 17 
samples.  
10 samples from the nipple without evidence of M. Paget were also included in the 
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study for the evaluation of Toker cells. Toker cells were diagnosed histologically as 
pale small cells in the epidermis without signs of atypia. Toker cells were 
immunhistochemically characterized as cytokeratin 7 positive and CEA / Her2 
negative cells. 
18 samples of mammary-like glands of the anogenital region were included in the 
analysis (10 of them also had EMPD). Mammary like glands were defined 
histologically as apo-eccrine glandular structures with morphological similarity to 
dilated mammary glands. Mammary-like glands, which are surrounded by two cell 
types are arranged into organoid tubulo-glandular areas resembling a ductulo-lobular 
unit of the breast. 
 
Histology 
The surgical specimens were fixed in 4% buffered formalin and submitted for 
histology. All MPD and EMPD diagnoses as well as the control cases were evaluated 
by two independent pathologists (OG & ZV). 3-4-micrometer sections from the 
paraffin-embedded tissue were taken for immunohistochemistry. All cases were 
routine stained by hematoxylin and eosin (H&E).  
 
Immunohistochemistry and fluorescence in situ hybridization (FISH) 
Immunohistochemistry was performed with the Ventana Benchmark automated 
staining system using Ventana reagents for the entire procedure. Primary antibodies 
were detected using the iVIEW DAB detection kit and the signal was enhanced using 
the amplification kit. Following markers and dilutions were used: NY-BR-1 17 
(Ludwig Institute, New York, USA) (1:400, concentration, 2 ug/ml), BRST-
2/GCDFP-15 (Signet Pathology Systems, Dedham, USA, Inc., additional dilution 
1:4), CK7 (DAKO, Baar, Switzerland, M7018, Dilution 1:100), CK20 (Progen 
Biotechnik, Heidelberg, Germany 61026, Dilution 1:10) and CEA (DAKO A/S 
Glostrup, Denmark, M0613, Dilution 1:20). NY-BR-1 immunohistochemistry was 
performed according to recent recommendation 17. To determine Her2 status on 
EMPD, the HER2 proto-oncogene was assessed by fluorescence in situ hybridization 
using direct fluorescent-labeled DNA probes obtained from Pathvysion (Vysis, Abott 
AG Diagnostic Division, Baar, Switzerland) and an Olympus microscope, as 
previously described 17. Her2 status and copy number analysis was carried out 
according to the current ASCO guidelines 22. 
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Scoring of immunohistochemistry for NY-BR-1 
Positive immunoreactivity for NY-BR-1 was defined as a positive reaction product in 
the cytoplasm (or also in the nucleus) of Paget cells, in an analogous way as reported 
previously in a large study on NY-BR-1 expression in breast cancer and its metastases 
as follows: focal staining of single cells or small clusters of cells (<10% positive 
cells); moderate staining (11-50% positive cells); and diffuse staining (51-100% 
positive cells). Differences in staining intensity were not considered17. 
Immunostaining for CK7, CK20 and CEA was defined as positive when at least 
single Paget-cells exhibited positive reaction. The extent of immunohistochemical 
reactivity was graded as follows: “+” focal staining of single cells or small clusters of 
cells (<10% positive cells); “++” moderate staining (11-50% positive cells); and 
“+++” diffuse staining (51-100% positive cells). Differences in staining intensity 
were not considered. 
 
RESULTS 
 
NY-BR-1 expression in mammary Paget’s disease  
Eighteen of 24 MPDs (75 %) showed NY-BR-1 expression (Table 1). NY-BR-1 
immunoreactivity scores in MPD were always identical to the immunoreactivity score 
in the underlying DCIS. However, in 3 of 15 MPDs (20%) with synchronous invasive 
breast cancer, a lower NY-BR-1 score was observed in the invasive carcinoma.  
 
NY-BR-1 expression in extra-mammary Paget’s disease  
Twenty-one of 26 EMPD cases (80.8%) demonstrated NY-BR-1 expression (Table 2) 
as follows: vulva (v): 18/21; paravulvar (pv): 0/1; perianal (pa): 1/1; anal (a): 2/2; 
preputium (p): 0/1 (Figures 1, 2, 4). Immunoreactivity score was high (+++) in 15 
(57.7%), intermediate (++) in 4 (15.4%) and low in 2 (7.7%) EMPDs. 
Two patients with local Paget recurrence were NY-BR-1 positive in the primary 
lesion but NY-BR-1 negative in the recurrent EMPD. Both biopsies were obtained 
from the vulvar region, in one patient (case 8) one year after the first biopsy, in the 
second patient (case 21) 19 years after the first biopsy. HER2 gene amplification was 
found in 6 of 26 EMPDs (23.1%), 5 of them were also NY-BR-1 positive (Table 2). 
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NY-BR-1 expression in control tissues (Table 3).   
Axillary apo-eccrine glands 
18 out of 48 eccrine glands of the axillary regions were positive for NY-BR-1 (37%). 
17 of 19 samples (90%) with apocrine glands in the axilla showed positivity for NY-
BR-1 (Figure 3). None of the 17 sebaceous glands exhibited NY-BR-1. 
Mammary-like glands of the anogenital regions 
17 of 18 samples (94%) with apocrine cells in the MLGs of the ano-genital region 
were positive for NY-BR-1 (Figures 2, 4). 4 out of 15 samples with  eccrine cells in 
MLG showed positivity for NY-BR-1 (36%). 
Toker cells of the nipple 
10 areolar samples with Toker cells were all negative for NY-BR-1. 
In situ skin squamous cell carcinomas  
12 skin samples with in situ squamous cell carcinoma were negative for NY-BR-1. 
Tissue micro array with endometrial carcinoma samples (n=382). 
All 382 spots with endometrium carcinomas were negative for NY-BR-1. 
 
NY-BR-1 immunoreactivity was observed in all cases as a nuclear and/or cytoplasmic 
reaction product.  
 
NY-BR-1 immunohistochemistry as a diagnostic marker 
The differential diagnosis of MPD and EMPD includes Toker cells of the epidermis, 
malignant melanoma in situ and pagetoid Bowen’s disease (PBD). Toker cells as well 
as all other cells of the epidermis were NY-BR-1 negative. Also, 12 cases of Bowen’s 
disease were NY-BR-1 negative in whole tissue sections. CK7, CK20, CEA and 
GCDFP-15 are frequently used to distinguish MPD and EMPD from PBD. CK 7 
expression was diffusely positive (+++) in all EMPDs (Table 2), whereas CK 20 
expression was present in only 18 cases (69%), CEA was positive in 23 of 24 EMPDs 
(95.8%). GCDFP-15 was positive in 22 cases (84.6%). 
One EMPD patient (patient 10) presented with a poorly differentiated 
adenocarcinoma of the uterus after yearly relapses of Paget’s disease of the vulva. 
This patient exhibited neither breast cancer nor another malignant tumor. The tumor 
cells in the uterus expressed NY-BR-1, confirming the H&E diagnosis of a recurrent 
EMPD in the endometrium. To prove the possibility of NY-BR-1 positivity in 
endometrioid cancer of the uterus, a tissue microarray with 382 endometrial 
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carcinomas was analyzed for NY-BR-1 expression. NY-BR-1 positivity was not 
observed. 
 
DISCUSSION 
In our analysis, a recently developed NY-BR-1-specific monoclonal antibody directed 
against an NY-BR-1 epitope between amino acid residues 851 to 921, corresponding 
to exons 27 to 30 of the NY-BR-1 gene was used. With this antibody, we have 
previously demonstrated in cell lines as well as in formalin-fixed and paraffin-
embedded tissue that NY-BR-1 is primarily a breast epithelium differentiation 
antigen, which is expressed in normal and neoplastic breast epithelium and in adnexal 
tumors of the skin. A specific, predominantly cytoplasmic staining combined with 
nuclear staining was shown by confocal microscopy 17. This staining property could 
be achieved at a dilution of 1: 400, which resulted in signals only in cells of the 
ductulo-lobular units and in breast cancer cells 17, 21. Our previous study on more than 
2000 breast carcinoma lesions has shown that NY-BR-1 expression is associated with 
tumor differentiation, HER2/neu-gene-, EGFR- and ER-status of breast cancer as well 
as with prognosis 21. It was also shown that NY-BR-1 expression is regulated by the 
estrogen receptor alpha 18. 
 
Based on these observations, we set out to study NY-BR-1 expression in mammary- 
and extramammary Paget’s disease. The present study shows for the first time that 
both EMPD and MPD are frequently NY-BR-1 positive. Compared to the results of 
our previous analyses 17, 21, the prevalence of NY-BR-1 expression in MPD and 
EMPD (75-80%) is similar to that of DCIS (79%) but higher than in invasive breast 
cancer (61%). As with several other differentiation antigens, NY-BR-1 demonstrates 
a lower expression in less differentiated and/or metastatic breast cancer. We have 
observed in our previous study that NY-BR-1 was more frequently expressed in grade 
1 breast cancer (82%) than in grade 2 (69%) or grade 3 (46%) invasive breast 
carcinomas. NY-BR-1 expression levels also decreased in lymph node and distant 
metastases 21.  
 
Even though MPD and EMPD are morphologically indistinguishable from each other, 
they differ in their HER2/neu amplification frequency. While MPD is reported to 
demonstrate HER2/neu amplification in 73-100% 23-25, only 7-43 % of EMPDs show 
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HER2 amplification 24-26. This is consistent with our FISH-analysis that demonstrated 
HER2/neu amplification in only 20% of EMPDs. MPDs are almost always associated 
with a synchronous in situ or invasive breast cancer. This may explain the higher rate 
of HER2/neu amplification in MPD compared to EMPD. 
 
The histogenesis of EMPD remains unclear. EMPD mainly develops in regions 
featuring apo-eccrine glands or MLGs, e.g. in the axilla or in the anogenital region. 
Therefore, MLGs 12-13 in the ano-genital region have been suggested as being a 
possible origin of EMPD. Toker cells of the epidermis, pluripotent stem cells and 
infiltrating urothelial carcinomas with involvement of the epidermis have also been 
discussed as being the origin of EMPD 4, 14-15. Here, we demonstrated in both sexes 
that apo-eccrine glands of the axilla and MLGs are NY-BR-1 positive, whereas Toker 
cells and all other epidermal cells were NY-BR-1 negative. Based on the fact that 
apo-eccrine glands and MLGs share common regions of occurrence and similar NY-
BR-1 phenotypes with Paget’s disease, we postulate that at least a subset of EMPD 
may derive from these structures, which could also explain the occurrence of breast-
like neoplasms such as phylloides tumor 19 and adenocarcinomas in the ano-genital 
region 13, 27. Interestingly, there was a predominant positivity for NY-BR-1 in the 
apocrine cell types over eccrine cell types both in MLG and skin appendage glands in 
the axilla. As apocrine differentiation often occurs in breast cancer, this observation in 
MLGs and axillary apo-eccrine glands would further support the hypothesis that 
MLGs, apocrine glands, EMPD and invasive breast cancer may be histogenetically 
related to each other.   
 
The differential diagnosis of MPD and EMPD includes superficial spreading variants 
of malignant melanoma in situ (MMIS) and pagetoid Bowen disease (PBD). S100 and 
HMB45 are specific and sensitive markers in distinguishing EMPD from MMIS 28. 
Lack of NY-BR-1 expression on the RNA and protein level has previously been 
shown in malignant melanoma 17, 29. When distinguishing MPD and EMPD from 
PBD, the antibodies CK7, CK20, CEA and GCDFP15 are frequently utilized 30-33. 
CK7 is highly sensitive for MPD as well as for EMPD, but it can also be positive in 
some cases of PBD. GCDFP-15 and CEA are more specific since they are clearly 
negative in squamous cell lesions 34. NY-BR-1 is slightly less sensitive than CEA or 
GCDFP-15, but in one of our patients CEA and GCDFP-15 were negative, while NY-
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BR-1 expression was positive. Furthermore, in one of our patients with recurrent 
EMPD, we observed NY-BR-1 expression in Paget cells invading the endometrium, 
while our tissue microarray analysis of 382 endometrial carcinomas confirmed that 
endometrial carcinomas are NY-BR-1 negative.  
As to the histogenesis of EMPD and related cells (Toker cells, mammary-like glands 
or apo-eccrine glands of the axilla), the differential expression of proteins other than 
NY-BR-1 is also of interest 15. There is some heterogeneity in the expression profile 
of these lesions: EMPDs for example can exhibit both ecto-or endodermal phenotype, 
resulting in being positive or negative for GCDFP-15 and CK20, which however does 
not influence the constant CK7 expression 35. Toker cells on the other hand 
consequently express CK7 and hormone receptors, can be positive for MUC1, but 
practically never express CEA, EMA S100, GCDFP15 or cytokeratin 20, similar to 
our experience in this study 14-15, 36. Mammary-like glands can exhibit a phenotype 
similar to that of the breast parenchyma, they are often hormone receptor and 
GCDFP-15 positive and as we could also demonstrate in this study, they can show an 
expression of the breast differentiation antigen, NY-BR-1 as well 37-38. Apoeccrine 
glands of the axilla have been shown to have similarity to breast phenotype, as being 
positive for GCDFP-15, CEA and S100 7. Interestingly, NY-BR-1 positivity in our 
study was found in a higher frequency among apocrine than in eccrine cell types in 
the axillary glands, providing further evidence for a histogenetical link between 
axillary glands and breast specific glands. 
Our findings on NY-BR-1 expression in EMPDs are consistent with the results from 
previous studies on immunohistochemical NY-BR-1 expression in non Paget’s breast 
cancer and suggest that NY-BR-1 can be added to an immunohistochemical panel for 
the characterization of MPD and EMPD in biopsy specimens of localized as well as 
of advanced disease 17, 21.  
 
In summary, this study demonstrates frequent expression of the breast differentiation 
antigen NY-BR-1 in MPD and EMPD. Our comprehensive immunohistochemical 
analysis of EMPD with a panel of different antibodies suggests that NY-BR-1 can be 
used as a diagnostic marker for MPD and EMPD. Furthermore our data provide 
evidence that some cases of Paget’s disease are potentially derived from apocrine 
cells of the MLGs of the ano-genital region or apo-eccrine glands of the axilla. 
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LEGEND OF FIGURES 
 
Figure 1 
NY-BR-1 expression in EMPD.  
Vulvar  (A,B,E) and anal EMPD (C,D) characterized by large eosinophilic atypical 
cells in the epidermis. 
A/C: H&E, B/D: NY-BR-1, E: HER2 (FISH). 
 
Figure 2 
NY-BR-1 expression in EMPD and in MLG. 
Vulvar EMPD and MLG. Arrow head indicates EMPD; arrows indicate MLG. 
Mammary like glands are characterized by dilated double layered glandular structures 
in the deeper areas of the vulva. 
A: H&E, B: NY-BR-1. 
 
Figure 3 
NY-BR-1 expression in apo-eccrine glands of the axilla. 
Apo-eccrine glands of the axilla are characterized by predominant eccrine and 
apocrine differentiated cells groups. 
A/C:  H&E, B/D: NY-BR-1. 
 
Figure 4 
NY-BR-1 expression in anal EMPD and anal MLG. 
Anal EMPD and MLG. Top of the figure: EMPD, arrows indicate MLG. Mammary 
like glands in the anal region are characterized by dilated double layered glandular 
structures, extramammary Paget cells are visible as large eosinophilic atypical cells in 
the lower epidermis. 
A: H&E, B: NY-BR-1. 
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Table 1. 
NY-BR-1 expression levels in mammary Paget’s disease and synchronous  ductal carcinoma 
in situ or invasive breast cancer 
 
 
Case Age CA DCIS Paget 
______________________________ 
 
1 40 +++ +++ +++ 
2 41 neg neg neg 
3 48 ** +++ +++ 
4 49 +++ +++ +++ 
5 49 +++ +++ +++ 
6 50 +++ ** +++ 
7 52 * * ++ 
8 55 neg ** + 
9 58 + ++ ++ 
10 59 neg +++ +++ 
11 61 ++ + + 
12 61 neg neg neg 
13 61 * * neg 
14 62 +++ +++ +++ 
15 62 +++ +++ +++ 
16 65 neg neg neg 
17 66 +++ +++ +++ 
18 70 neg ** neg 
19 73 ++ ++ ++ 
20 76 neg +++ +++ 
21 78 * * +++ 
22 79 +++ +++ +++ 
23 79 neg neg neg 
24 80 ++ ++ ++ 
 
 
CA: invasive breast carcinoma. DCS: ductal carcinoma in situ. * indicates Paget only. 
** indicates not present. ‘neg’ indicates negative results. +-+++: for definition see text. 
Age in years. 
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Table 2 
Extramammary Paget’s disease: immunohistochemistry and Her2/FISH amplification.  
 
Case location age/gender NY-BR1 GCDFP-15 CK7 CK20 CEA HER2/FISH
  
________________________________________________________________________________________ 
 
1 vulva 44/female +++  +  +++ ++ + pos  
2 vulva 46/female neg  neg  +++ + +++ pos 
3 vulva 47/female +++  neg  +++ ++ neg neg 
4 vulva 57/female +  ++  +++ ++ +++ pos  
4a vulva 59/female +  ++  +++ ++ +++ pos 
5 vulva 59/female +++  ++  +++ +++ ++ neg 
6 vulva 61/female ++  +++  +++ neg +++ neg 
7 vulva 63/female neg  neg  +++ neg + neg 
8 vulva 64/female +++  +++  +++ ++ +++ neg 
8a vulva 88/female neg  +++  +++ ++ +++ neg 
9 vulva 65/female ++  +++  +++ ++ +++ neg 
10 vulva 66/female ++  ++  +++ +++ +++ neg  
10a uterus 71/female +++  ++  +++ +++ +++ pos 
11 vulva 69/female +++  +++  +++ + +++ neg 
12 vulva 72/female +++  +++  +++ neg +++ pos 
13 vulva 74/female +++  +++  +++ +++ + neg 
14 vulva 78/female ++  +++  +++ neg +++ neg 
15 vulva 80/female +  +  +++ neg + neg  
16 vulva 80/female +++  +++  +++ ++ +++ neg 
16a vulva 81/female +++  +++  +++ ++ +++ neg 
17 vulva 82/female +++  ++  +++ + +++ neg 
18 vulva 84/female +++  +++  +++ neg ++ neg 
19 vulva 84/female +++  neg  +++ neg * pos 
20 vulva 86/female neg  +++  +++ neg ++ neg  
20a vulva 91/female neg  +++  +++ neg ++ neg 
21 vulva 89/female +++  +++  +++ ++ +++ neg 
21a vulva 94/female neg  +++  +++ ++ +++ neg 
22 vulvar° 85/female neg  +++  +++ +++ +++ neg 
23 anal 73/male  +++  +++  +++ + + neg 
24 anal 77/male  +++  +++  +++ neg +++ neg 
25 perianal 84/male  +++  +  +++ ++ +++ neg 
26 penis°° 87/male  neg  +++  +++ + * neg 
 
 
"a": recurrent extramammary Paget’s Disease. “pos”: HER2 gene amplification by fluorescence in situ 
hybridization (FISH). “neg” indicates negative test result. * indicates no result available. +-+++ : for definition 
see text. Age in years. °: exact location: paravulvar. °°: exact location: preputium. 
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Table 3 
Immunohistochemical NY-BR-1 expression in other locations and cell types (skin appendage 
glands in the axilla, Toker cells of the nipple, in situ squamous cell carcinoma of the skin, 
mammary-like glands of the anogenital region, endometrial carcinomas). 
 
 
      positive stain   negative stain   
___________________________________________________________________ 
 
Axillary skin appendage glands  
 
Eccrine glands (n=48)  18 (37%)  30 (63%)   
 
Apocrine glands (n=19)  17 (90%)  2 (10%)   
 
Sebaceous glands (n=17)  0   17 (100%) 
 
Mammary like glands  
(apo-eccrine glands)  
Apocrine cells (n=18)  17 (94%)  1 (6%) 
  
Eccrine cells (n=15)   4 (36%)  11 (73%) 
 
Toker cells of the nipple  
(n=10)     0   10 (100%) 
 
In situ skin squamous cell carcinoma  
 (n=12)     0   12 (100%) 
 
Tissue micro array with 
endometrial carcinomas (n=382)  0   382 (100%) 
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